Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
25
02
2019
entrez:
11
9
2020
pubmed:
16
5
2019
medline:
16
5
2019
Statut:
epublish
Résumé
Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for The cohort comprised eight patients with AP-IMT treated with crizotinib and surgery. Outcome measures were progression-free and overall survival after commencing crizotinib, treatment-related toxicities, features associated with relapse, outcome after relapse, and outcome after ceasing crizotinib. The median follow-up after commencing crizotinib was 3 years (range, 0.9 to 5.5 years). The major toxicity was neutropenia. All patients responded to crizotinib. Five were able to discontinue therapy without recurrence (median treatment duration, 1 year; range, 0.2 to 3.0 years); one continues on crizotinib. Two critically ill patients with initial complete response experienced relapse while on therapy. Both harbored We confirm acceptable toxicity and excellent disease control in patients with AP-IMT treated with crizotinib, which may be ceased without recurrence in most. Relapses occurred in two of three patients with
Identifiants
pubmed: 32914017
doi: 10.1200/PO.18.00297
pii: 1800297
pmc: PMC7446396
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2019 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Toby TrahairStock and Other Ownership Interests: CSLAndrew C. WoodPatents, Royalties, Other Intellectual Property: PAT055863-US-PCT, inventor assigned to Genomics Institute of the Novartis Research Foundation involving combination inhibition of ALKTim R. MercerSpeakers’ Bureau: Oxford Nanopore Patents, Royalties, Other Intellectual Property: Inventor of two patents related to synthetic RNA and DNA controls for next-generation sequencingKaren L. MacKenzieResearch Funding: Komipharm (Inst) No other potential conflicts of interest were reported.
Références
Diagn Pathol. 2016 Jul 27;11(1):67
pubmed: 27460384
Jpn J Clin Oncol. 2014 Sep;44(9):868-71
pubmed: 25028698
Int J Clin Exp Pathol. 2015 Apr 01;8(4):4213-9
pubmed: 26097614
J Thorac Oncol. 2019 May;14(5):825-834
pubmed: 30550870
Clin Cancer Res. 2016 Aug 1;22(15):3810-20
pubmed: 26994145
Blood Cancer J. 2016 Aug 05;6(8):e456
pubmed: 27494825
Cancer Res. 1999 Jun 15;59(12):2776-80
pubmed: 10383129
N Engl J Med. 2016 Jan 7;374(1):95-6
pubmed: 26736010
Int J Hematol. 2014 Feb;99(2):202-7
pubmed: 24307515
Am J Surg Pathol. 2017 Jun;41(6):773-780
pubmed: 28490045
J Pathol. 2017 Feb;241(3):316-323
pubmed: 27874193
Eur J Pediatr Surg. 2017 Aug;27(4):319-323
pubmed: 27699733
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Am J Pathol. 2001 Aug;159(2):411-5
pubmed: 11485898
Pediatr Blood Cancer. 2018 Jun;65(6):e27012
pubmed: 29480552
Blood. 2003 Oct 1;102(7):2638-41
pubmed: 12750159
Mod Pathol. 2001 Jun;14(6):569-76
pubmed: 11406658
Pathol Res Pract. 2011 Sep 15;207(9):587-91
pubmed: 21855232
Histopathology. 2016 Jul;69(1):72-83
pubmed: 26647767
Cancer Res Treat. 2016 Jan;48(1):398-402
pubmed: 25715771
Mod Pathol. 2015 May;28(5):732-9
pubmed: 25612511
J Pediatr Surg. 2011 Apr;46(4):e17-e21
pubmed: 21496520
Pediatr Hematol Oncol. 2013 Oct;30(7):640-5
pubmed: 23988029
Blood. 2000 May 15;95(10):3204-7
pubmed: 10807789
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
N Engl J Med. 2010 Oct 28;363(18):1727-33
pubmed: 20979472
Hum Pathol. 2004 Oct;35(10):1285-8
pubmed: 15492998
Blood. 2003 Oct 1;102(7):2568-73
pubmed: 12763927
Cancer Discov. 2014 Aug;4(8):889-95
pubmed: 24875859
Genes Chromosomes Cancer. 2002 Aug;34(4):354-62
pubmed: 12112524
Genes Chromosomes Cancer. 2003 May;37(1):98-105
pubmed: 12661011
Mod Pathol. 2003 Aug;16(8):828-32
pubmed: 12920229
Am J Surg Pathol. 2001 Nov;25(11):1364-71
pubmed: 11684952
Am J Surg Pathol. 2016 Aug;40(8):1051-61
pubmed: 27259007
Nat Protoc. 2014 May;9(5):989-1009
pubmed: 24705597
Int J Surg Pathol. 2014 Oct;22(7):640-4
pubmed: 24583837
J Clin Oncol. 2017 Oct 1;35(28):3215-3221
pubmed: 28787259
Blood. 2018 Apr 5;131(14):1576-1586
pubmed: 29437595
J Clin Oncol. 2012 Jun 20;30(18):2190-6
pubmed: 22614995
J Thorac Oncol. 2017 May;12(5):804-813
pubmed: 28147239
Cancer Chemother Pharmacol. 2017 Jan;79(1):181-187
pubmed: 28032129
Methods. 2013 Sep 1;63(1):41-9
pubmed: 23816787
Am J Surg Pathol. 2015 Jul;39(7):957-67
pubmed: 25723109
PLoS One. 2011 Apr 08;6(4):e18436
pubmed: 21494621
Clin Cancer Res. 2011 May 15;17(10):3341-8
pubmed: 21430068
Lancet Oncol. 2013 May;14(6):472-80
pubmed: 23598171
Am J Pathol. 2000 Aug;157(2):377-84
pubmed: 10934142
Genes Chromosomes Cancer. 2014 Jan;53(1):78-89
pubmed: 24142740
Haematologica. 2011 Feb;96(2):343-6
pubmed: 21109691
Am J Surg Pathol. 2011 Jan;35(1):135-44
pubmed: 21164297
Pediatr Blood Cancer. 2015 May;62(5):909-11
pubmed: 25682942
J Thorac Oncol. 2014 Mar;9(3):295-306
pubmed: 24518086
Haematologica. 2010 Mar;95(3):509-13
pubmed: 20207848
Orphanet J Rare Dis. 2017 May 23;12(1):97
pubmed: 28535796
Int J Cancer. 2006 Mar 1;118(5):1181-6
pubmed: 16161041
Int J Clin Exp Pathol. 2015 May 01;8(5):5803-7
pubmed: 26191301
Lancet Respir Med. 2018 Jun;6(6):431-441
pubmed: 29669701